{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:27:58Z","timestamp":1785421678512,"version":"3.56.0"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2022LCYJ-MS27"],"award-info":[{"award-number":["2022LCYJ-MS27"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2022LCYJ-MS27"],"award-info":[{"award-number":["2022LCYJ-MS27"]}],"id":[{"id":"https:\/\/ror.org\/026axqv54","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Nanjing Health and Health Commission","award":["ZDX22001"],"award-info":[{"award-number":["ZDX22001"]}]},{"award":["ZDX22001"],"award-info":[{"award-number":["ZDX22001"]}],"id":[{"id":"https:\/\/ror.org\/0067hwx77","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The immunologically cold nature and immunosuppressive tumor microenvironment (TME) of intrahepatic cholangiocarcinoma (ICC) contribute to its poor prognosis. This study aims to identify novel biomarkers related to prognosis and TME in ICC. Methods: We first identified the high expression of m6A reader insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) in ICC through bioinformatics screening. Subsequently, a retrospective study was conducted on 224 ICC patients who had undergone radical resection. The expression levels of IGF2BP2 and programmed death ligand 1 (PD-L1) were detected in a tissue microarray (TMA) using immunohistochemistry (IHC). The co-localization of IGF2BP2, PD-L1, programmed cell death protein 1 (PD-1), and CD8+T cells was evaluated by multiple immunofluorescence techniques. Results: IHC confirmed a significant upregulation of IGF2BP2 in tumor tissues compared with normal bile duct epithelia (p &lt; 0.05). IGF2BP2 expression was positively correlated with PD-L1 expression (TPS R = 0.215, p = 0.016; CPS R = 0.295, p = 0.008). High IGF2BP2 expression was associated with increased PD-L1\/PD-1 positivity and reduced CD8+T cell infiltration. Kaplan\u2013Meier analysis revealed significantly worse 3-year overall survival (OS: 20.56% vs. 29.91%, p = 0.0291) and recurrence-free survival (RFS: 9.72% vs. 18.56%, p = 0.0372) in the IGF2BP2-high group. Multivariate analysis identified IGF2BP2 as an independent risk factor for both OS (HR = 1.683, p = 0.044) and RFS (HR = 1.946, p = 0.042). Conclusions: IGF2BP2, as a potential biomarker and independent prognostic factor for ICC, is associated with increased PD-L1 expression.<\/jats:p>","DOI":"10.3390\/biomedicines14040929","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:22:47Z","timestamp":1776691367000},"page":"929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IGF2BP2 Overexpression Predicts Poor Prognosis and Correlates with PD-L1 Expression in Intrahepatic Cholangiocarcinoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0206-2020","authenticated-orcid":false,"given":"Jianan","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China"},{"name":"Public Experimental Platform, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5140-4872","authenticated-orcid":false,"given":"Xintao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexuan","family":"Hui","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxiang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"Public Experimental Platform, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-4615","authenticated-orcid":false,"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"ref_1","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2011.11.015","article-title":"Rising Trends in Cholangiocarcinoma: Is the Icd Classification System Misleading Us?","volume":"56","author":"Khan","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3350\/cmh.2021.0287","article-title":"Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance","volume":"28","author":"Komuta","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41467-023-35896-4","article-title":"Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s00018-012-1186-z","article-title":"Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression?","volume":"70","author":"Bell","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-022-01224-4","article-title":"RNA demethylase ALKBH5 in cancer: From mechanisms to therapeutic potential","volume":"15","author":"Qu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.tem.2020.05.007","article-title":"The diverse functions of IMP2\/IGF2BP2 in metabolism","volume":"31","author":"Dai","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12935-021-01799-x","article-title":"The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers","volume":"21","author":"Wang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3892\/mmr.2025.13441","article-title":"Multifaceted roles of insulin-like growth factor 2 mRNA binding protein 2 in human cancer (Review)","volume":"31","author":"Shen","year":"2025","journal-title":"Mol. Med. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ruff, S.M., Shannon, A.H., and Pawlik, T.M. (2022). Advances in targeted immunotherapy for hepatobiliary cancers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213961"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Xian, F., Ren, D., Bie, J., and Xu, G. (2023). Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: A meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1119168"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00595-020-01967-y","article-title":"Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma","volume":"50","author":"Asahi","year":"2020","journal-title":"Surg. Today"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0787","DOI":"10.1097\/HC9.0000000000000787","article-title":"Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: Difference of TACE combined with antiangiogenics and immunotherapy","volume":"9","author":"He","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-022-01272-w","article-title":"LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Elcheva, I.A., Gowda, C.P., Bogush, D., Gornostaeva, S., Fakhardo, A., Sheth, N., Kokolus, K.M., Sharma, A., Dovat, S., and Uzun, Y. (2023). IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1224516"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/cas.16136","article-title":"WTAP-induced N(6)-methyladenosine of PD-L1 blocked T-cell-mediated antitumor activity under hypoxia in colorectal cancer","volume":"115","author":"Liu","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1186\/s12967-024-05498-9","article-title":"CircRHBDD1 promotes immune escape via IGF2BP2\/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ibra.12150","article-title":"IGF2BP2 modulates autophagy and serves as a prognostic marker in glioma","volume":"10","author":"Li","year":"2024","journal-title":"Ibrain"},{"key":"ref_22","first-page":"171","article-title":"Three liquid-liquid phase separation-related genes associated with prognosis in glioma","volume":"17","author":"Lv","year":"2024","journal-title":"Pharmacogenom. Pers. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Deng, X., Jiang, Q., Liu, Z., and Chen, W. (2020). Clinical significance of an m6A reader gene, IGF2BP2, in head and neck squamous cell carcinoma. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00068"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41420-023-01669-7","article-title":"IGF2BP2 acts as a m6A modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization","volume":"9","author":"Tang","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7150\/ijms.74751","article-title":"Cytoplasmic IGF2BP2 protein expression in human patients with oral squamous cell carcinoma: Prognostic and clinical implications","volume":"19","author":"Lin","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40246-024-00632-6","article-title":"Systematic analysis of IGF2BP family members in non-small-cell lung cancer","volume":"18","author":"Gong","year":"2024","journal-title":"Hum. Genom."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jia, M., Shi, Y., Xie, Y., Li, W., Deng, J., Fu, D., Bai, J., Ma, Y., Zuberi, Z., and Li, J. (2021). WT1-AS\/IGF2BP2 axis is a potential diagnostic and prognostic biomarker for lung adenocarcinoma according to ceRNA network comprehensive analysis combined with experiments. Cells, 11.","DOI":"10.3390\/cells11010025"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"49743","DOI":"10.18632\/oncotarget.10439","article-title":"Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2\/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma","volume":"7","author":"Barghash","year":"2016","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101948","DOI":"10.1016\/j.mcp.2023.101948","article-title":"Pancancer analysis uncovers an immunological role and prognostic value of the m6A reader IGF2BP2 in pancreatic cancer","volume":"73","author":"Deng","year":"2024","journal-title":"Mol. Cell. Probes"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dahlem, C., Barghash, A., Puchas, P., Haybaeck, J., and Kessler, S.M. (2019). The insulin-like growth factor 2 mRNA binding protein IMP2\/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133204"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.189.7.1101","article-title":"A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma","volume":"189","author":"Zhang","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0002-9440(10)61770-1","article-title":"Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis","volume":"159","author":"Lu","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12943-020-01190-w","article-title":"m(6)A-dependent glycolysis enhances colorectal cancer progression","volume":"19","author":"Shen","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"117225","DOI":"10.1016\/j.biopha.2024.117225","article-title":"A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)","volume":"178","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.21037\/tcr-21-561","article-title":"A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets","volume":"10","author":"Cai","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"108198","DOI":"10.1016\/j.compbiomed.2024.108198","article-title":"Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma","volume":"171","author":"Gong","year":"2024","journal-title":"Comput. Biol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/08923973.2024.2402338","article-title":"Treatment, and Outcome of Nivolumab-Induced Cholangitis","volume":"46","author":"He","year":"2024","journal-title":"Immunopharmacol. Immunotoxicol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/4\/929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:28:02Z","timestamp":1777004882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/14\/4\/929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["biomedicines14040929"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines14040929","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}